Answers are grounded in this paper and cite their sources.
BACKGROUND: Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular disorder characterized by the absence of dystrophin, leading to progressive skeletal and cardiac muscle degeneration. Cardiomyopathy is a leading cause of morbidity and mortality in patients with DMD, often manifesting as a dilated cardiomyopathy with myocardial fibrosis and arrhythmia. Mineralocorticoid receptor antagonists, including the nonsteroidal agent finerenone, have emerged as disease-modifying therapies because of their antifibrotic, anti-inflammatory, and cardioprotective properties. CASE SUMMARY: A 45-year-old man with DMD and progressive nonischemic cardiomyopathy was initiated on finerenone in addition to guideline-directed medical therapy. Over 16 months, he demonstrated improvement in left ventricular ejection fraction and ventricular remodeling without adverse effects. DISCUSSION: Finerenone is a nonsteroidal mineralocorticoid receptor antagonist with potent antifibrotic and anti-inflammatory properties. This case highlights its potential role in DMD cardiomyopathy, where fibrosis is central to disease progression. TAKE-HOME MESSAGE: Finerenone may represent a novel therapy in DMD-associated cardiomyopathy and warrants further investigation for use in this population.
No takes yet. Share an insight, caveat, or question.
Hillyer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: